Royce & Associates LP Pacira Bio Sciences, Inc. Transaction History

Royce & Associates LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$30.68 - $40.09 $3.61 Million - $4.71 Million	-117,579 Reduced 94.53%	6,803 $208,000
Q2 2023 Aug 07, 2023	BUY	$36.12 - $47.5 $4.49 Million - $5.91 Million	124,382 New	124,382 $4.98 Million
Q2 2021 Aug 06, 2021	SELL	$59.18 - $69.99 $6.81 Million - $8.06 Million	-115,157 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$59.31 - $78.82 $2.49 Million - $3.31 Million	-41,933 Reduced 26.69%	115,157 $8.07 Million
Q4 2020 Feb 08, 2021	BUY	$50.47 - $66.26 $184,064 - $241,650	3,647 Added 2.38%	157,090 $9.4 Million
Q3 2020 Nov 12, 2020	SELL	$51.97 - $63.0 $616,208 - $746,991	-11,857 Reduced 7.17%	153,443 $9.23 Million
Q2 2020 Aug 07, 2020	BUY	$30.8 - $52.47 $5.06 Million - $8.63 Million	164,426 Added 18813.04%	165,300 $8.67 Million
Q1 2020 May 12, 2020	BUY	$28.4 - $50.7 $1,647 - $2,940	58 Added 7.11%	874 $29,000
Q4 2019 Feb 06, 2020	SELL	$36.31 - $46.83 $8,859 - $11,426	-244 Reduced 23.02%	816 $37,000
Q3 2019 Nov 13, 2019	BUY	$35.66 - $44.99 $37,799 - $47,689	1,060 New	1,060 $40,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.